Product image of Lifog (Latanoprost) supplied by GNH India

Lifog

Active Ingredient:
Latanoprost
Origin:
EU

Lifog (Latanoprost)

Latanoprost, the active ingredient in Lifog, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for the treatment of primary open‑angle glaucoma and ocular hypertension in adult patients. The medication works by enhancing fluid outflow, thereby helping to preserve visual function.

GNH India supplies Lifog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery and regulatory compliance across multiple regions.

Manufacturer / TM Owner

Trb Chemedica Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Latanoprost is used to lower intra‑ocular pressure in glaucoma‑related conditions.

  • Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression.
  • Ocular hypertension: lowers eye pressure to prevent development of glaucoma.
  • Secondary open‑angle glaucoma (including pseudoexfoliative): improves aqueous outflow to control pressure.

How It Works

  • Latanoprost is a prostaglandin F2α analogue that binds to FP receptors in the ciliary body. Activation of these receptors remodels the extracellular matrix of the uveoscleral pathway, increasing aqueous humor outflow through this route. The enhanced outflow reduces intra‑ocular pressure, providing therapeutic control of glaucoma and ocular hypertension. The effect is sustained with once‑daily dosing and does not rely on trabecular meshwork function.

Side Effects

Latanoprost may cause ocular and peri‑ocular adverse reactions, which are classified by frequency.

Common Side Effects

  • Eye redness: transient hyperemia of the conjunctiva.
  • Increased eyelash growth: longer, thicker lashes may appear.
  • Iris pigmentation: gradual darkening of the iris color.
  • Eye irritation: burning or stinging sensation after instillation.
  • Blurred vision: temporary reduction in visual clarity.

Serious or Rare Side Effects

  • Severe eye inflammation: uveitis or iritis requiring medical attention.
  • Allergic reaction: swelling, itching, or rash around the eye.
  • Corneal edema: swelling of the cornea that can affect vision.
  • Paradoxical rise in intra‑ocular pressure: unexpected pressure increase.
  • Vision loss: rare but possible loss of visual acuity.

Precautions & Warnings

When prescribing Latanoprost, clinicians should observe several precautionary measures to ensure safety and efficacy.

  • Monitor intra‑ocular pressure: assess IOP regularly after initiation.
  • Contraindicated in active ocular infection: avoid use during conjunctivitis or keratitis.
  • Caution in patients with a history of uveitis: may exacerbate inflammation.
  • Avoid contact lens wear for 15 minutes after instillation: reduce drug absorption on lens.
  • Use with caution in herpetic eye disease: may trigger reactivation.
  • Store at room temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Latanoprost can interact with other ophthalmic agents, influencing efficacy or safety.

Major Interactions (Avoid)

  • Concurrent use with other prostaglandin analogues: additive effect may increase risk of ocular side effects.
  • Combination with ocular anesthetics containing preservatives: may enhance corneal irritation.

Moderate Interactions (Monitor Closely)

  • Co‑administration with non‑steroidal anti‑inflammatory eye drops: may alter prostaglandin metabolism.
  • Use together with beta‑blocker eye drops: additive intra‑ocular pressure reduction may cause hypotony.
  • Systemic carbonic anhydrase inhibitors: potential for increased ocular irritation.
  • Anticholinergic eye medications: possible reduction in Latanoprost efficacy.

Frequently Asked Questions

Lifog contains the prostaglandin analogue latanoprost and is prescribed to lower intra‑ocular pressure in adults with primary open‑angle glaucoma or ocular hypertension, helping to slow disease progression and reduce the risk of vision loss.

Latanoprost binds to FP receptors in the eye’s ciliary body, remodeling the extracellular matrix of the uveoscleral pathway. This increases the outflow of aqueous humor, thereby decreasing intra‑ocular pressure and providing therapeutic control of glaucoma‑related conditions.

The prescribed regimen is determined by the treating eye‑care professional. Typically, one drop of the ophthalmic solution is instilled in the affected eye(s) once daily in the evening, but exact dosing should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To place an order, submit an enquiry on the Lifog product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost is a prostaglandin analogue, generally offering once‑daily dosing and a strong intra‑ocular pressure‑lowering effect. Compared with beta‑blocker drops such as timolol, latanoprost often provides greater pressure reduction with a different side‑effect profile, making it a common first‑line option for many patients.

Lifog should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from direct light and moisture, and keep it out of reach of children. Do not freeze the solution.

Lifog is applied as a single drop to the conjunctival sac of the affected eye(s) once daily, usually in the evening. The patient should wash hands before use, avoid touching the tip of the bottle to the eye or any surface, and wait at least 15 minutes before inserting contact lenses.

Serious adverse events, although rare, include severe eye inflammation (uveitis or iritis), paradoxical increase in intra‑ocular pressure, corneal edema, and allergic reactions that may cause swelling or rash around the eye. Any sudden visual changes or severe discomfort should prompt immediate medical evaluation.

Lifog is contraindicated in patients with active ocular infections, such as conjunctivitis or keratitis, and in those with known hypersensitivity to latanoprost or any component of the formulation. Caution is also advised for individuals with a history of uveitis or herpetic eye disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Latanoprost

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT